AstraZeneca, a global, science-led biopharmaceutical company, agreed to invest $245m in Cellectis, a clinical-stage biotechnology company. “We believe AstraZeneca is the perfect match to Cellectis by providing world-class expertise in the development and the commercialization of innovative medicines. This collaboration will allow us to leverage our pioneering research in gene editing and cell therapies, as well as our cutting-edge capabilities in manufacturing with the ambition to bring potentially life-saving therapies to patients with unmet medical need,” André Choulika, Cellectis CEO.